Bemcentinib is a potent, selective and orally bioavailable AXL inhibitor and the furthest along in clinical trials.
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. In preclinical studies, bemcentinib was shown to have an effect as a single agent therapeutic in the prevention and reversal of acquired resistance to standard of care cytotoxics and targeted therapies and may also slow or prevent tumor metastasis.
Rigel received an upfront payment and is eligible for milestone payments, potential sublicensing revenue as well as tiered royalties on any future net sales of commercialized products.
Development of bemcentinib:
KEYTRUDA is a trademark of Merck Sharp & Dohme Corp
Tarceva is a trademark of OSI Pharmaceuticals